The Oncology Institute, Inc. (TOI) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 13.7% | -15.3% | -16.4% |
| 2023 | 18.4% | -23.8% | -25.6% |
| 2022 | 20.6% | -32.5% | 0.1% |
| 2021 | 20.1% | -22.6% | -5.4% |
| 2020 | 19.7% | -4.4% | -7.6% |
Download Data
Export TOI earnings history in CSV or JSON format
Free sign-in required to download data
The Oncology Institute, Inc. (TOI) Earnings Overview
As of March 1, 2026, The Oncology Institute, Inc. (TOI) reported trailing twelve-month net income of -$66M, reflecting +0.2% year-over-year growth. The company earned $-0.07 per diluted share over the past four quarters, with a net profit margin of -0.2%.
Looking at the long-term picture, TOI's historical earnings data spans multiple years. The company achieved its highest annual net income of $152,000 in fiscal 2022.
The Oncology Institute, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including FMS ($978M net income, 0.0% margin), DVA ($747M net income, 0.1% margin), CCM (-$163M net income, -0.8% margin), TOI has room to improve margins relative to the peer group. Compare TOI vs FMS →
Peer Comparison
Earnings metrics vs industry competitors
| Company | TTM Net Income | TTM EPS | Net Margin | ROE | YoY Growth | Compare |
|---|---|---|---|---|---|---|
TOICurrent | -$66M | $-0.07 | -0.2% | -2.1% | +0.2% | — |
FMS | $978M | $1.71 | 0.0% | 0.1% | +0.8% | |
DVA | $747M | $8.48 | 0.1% | 0.5% | -0.2% | |
CCM | -$163M | $-1120.21 | -0.8% | -0.2% | -0.0% |
Historical Data
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$65M | +22.2% | -$60M | $-0.71 | -16.4% | -15.3% |
| 2023 | -$83M | -54750.0% | -$77M | $-0.92 | -25.6% | -23.8% |
| 2022 | $152,000 | +101.4% | -$82M | $-0.21 | 0.1% | -32.5% |
| 2021 | -$11M | +23.7% | -$46M | $-0.16 | -5.4% | -22.6% |
| 2020 | -$14M | -256.1% | -$8M | $-0.24 | -7.6% | -4.4% |
| 2019 | -$4M | - | -$3M | $-0.06 | -2.6% | -1.7% |
See TOI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TOI vs AGIO
See how TOI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TOI growing earnings?
TOI EPS of $-0.07 reflects slowing growth at +0.2%, below the 5-year CAGR of N/A. TTM net income is $-66M. Expansion rate has moderated.
What are TOI's profit margins?
The Oncology Institute, Inc. net margin is -0.2%, with operating margin at -0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are TOI's earnings?
TOI earnings data spans 2019-2024. The current earnings trend is +0.2% YoY. Historical data enables comparison across business cycles.